{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:17:18Z","timestamp":1790662638346,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1007\/s11255-017-1644-5","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T08:49:35Z","timestamp":1500886175000},"page":"1731-1740","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":89,"title":["Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"49","author":[{"given":"Binbin","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongming","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"key":"1644_CR1","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.eururo.2010.02.020","volume":"57","author":"K Hatzimouratidis","year":"2010","unstructured":"Hatzimouratidis K, Amar E, Eardley I, Giuliano F, Hatzichristou D et al (2010) Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 57:804\u2013814","journal-title":"Eur Urol"},{"key":"1644_CR2","first-page":"124","volume":"24","author":"BO Oyelade","year":"2016","unstructured":"Oyelade BO, Jemilohun AC, Aderibigbe SA (2016) Prevalence of erectile dysfunction and possible risk factors among men of South-Western Nigeria: a population based study. Pan Afr Med J 24:124","journal-title":"Pan Afr Med J"},{"key":"1644_CR3","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/0019-5545.158143","volume":"57","author":"RT Sathyanarayana","year":"2015","unstructured":"Sathyanarayana RT, Darshan MS, Tandon A (2015) An epidemiological study of sexual disorders in south Indian rural population. Indian J Psychiatry 57:150\u2013157","journal-title":"Indian J Psychiatry"},{"key":"1644_CR4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/2008-7802.157472","volume":"6","author":"MA Ramezani","year":"2015","unstructured":"Ramezani MA, Ahmadi K, Ghaemmaghami A, Marzabadi EA, Pardakhti F (2015) Epidemiology of sexual dysfunction in Iran: a systematic review and meta-analysis. Int J Prev Med 6:43","journal-title":"Int J Prev Med"},{"key":"1644_CR5","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/andr.12104","volume":"3","author":"Z Zhang","year":"2015","unstructured":"Zhang Z, Li Z, Yu Q, Wu C, Lu Z et al (2015) The prevalence of and risk factors for prostatitis-like symptoms and its relation to erectile dysfunction in Chinese men. Andrology 3:1119\u20131124","journal-title":"Andrology"},{"key":"1644_CR6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1046\/j.1464-410x.1999.00142.x","volume":"84","author":"IA Ayta","year":"1999","unstructured":"Ayta IA, McKinlay JB, Krane RJ (1999) The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int 84:50\u201356","journal-title":"BJU Int"},{"key":"1644_CR7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14740338.2016.1131818","volume":"15","author":"E Ventimiglia","year":"2016","unstructured":"Ventimiglia E, Capogrosso P, Montorsi F, Salonia A (2016) The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction. Expert Opin Drug Saf 15:141\u2013152","journal-title":"Expert Opin Drug Saf"},{"key":"1644_CR8","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1517\/14656566.2013.799665","volume":"14","author":"R Bruzziches","year":"2013","unstructured":"Bruzziches R, Francomano D, Gareri P, Lenzi A, Aversa A (2013) An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother 14:1333\u20131344","journal-title":"Expert Opin Pharmacother"},{"key":"1644_CR9","doi-asserted-by":"crossref","first-page":"369","DOI":"10.12688\/f1000research.7885.1","volume":"5","author":"CK Patel","year":"2016","unstructured":"Patel CK, Bennett N (2016) Advances in the treatment of erectile dysfunction: what\u2019s new and upcoming? F1000Res 5:369\u2013375","journal-title":"F1000Res"},{"key":"1644_CR10","first-page":"99","volume":"3","author":"AA Raheem","year":"2009","unstructured":"Raheem AA, Kell P (2009) Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil. Patient Prefer Adherence 3:99\u2013104","journal-title":"Patient Prefer Adherence"},{"key":"1644_CR11","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/j.1939-4640.2002.tb02323.x","volume":"23","author":"AD Seftel","year":"2002","unstructured":"Seftel AD (2002) Challenges in oral therapy for erectile dysfunction. J Androl 23:729\u2013736","journal-title":"J Androl"},{"key":"1644_CR12","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2147\/PPA.S56002","volume":"9","author":"JD Evans","year":"2015","unstructured":"Evans JD, Hill SR (2015) A comparison of the available phosphodiesterase-5 inhibitors in the treatment of erectile dysfunction: a focus on avanafil. Patient Prefer Adherence 9:1159\u20131164","journal-title":"Patient Prefer Adherence"},{"key":"1644_CR13","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.eururo.2013.01.012","volume":"63","author":"J Yuan","year":"2013","unstructured":"Yuan J, Zhang R, Yang Z, Lee J, Liu Y et al (2013) Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 63:902\u2013912","journal-title":"Eur Urol"},{"key":"1644_CR14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/sj.ijir.3901395","volume":"18","author":"MM Berner","year":"2006","unstructured":"Berner MM, Kriston L, Harms A (2006) Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations. Int J Impot Res 18:229\u2013235","journal-title":"Int J Impot Res"},{"key":"1644_CR15","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.eururo.2015.03.031","volume":"68","author":"L Chen","year":"2015","unstructured":"Chen L, Staubli SE, Schneider MP, Kessels AG, Ivic S et al (2015) Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. Eur Urol 68:674\u2013680","journal-title":"Eur Urol"},{"key":"1644_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17:1\u201312","journal-title":"Control Clin Trials"},{"issue":"4","key":"1644_CR17","doi-asserted-by":"crossref","first-page":"500","DOI":"10.4103\/1008-682X.175782","volume":"19","author":"WJ Bai","year":"2017","unstructured":"Bai WJ, Li HJ, Jin JJ et al (2017) A randomized clinical trial investigating treatment choice in Chinese men receiving sildenafil citrate and tadalafil for treating erectile dysfunction. Asian J Androl 19(4):500\u2013504","journal-title":"Asian J Androl"},{"key":"1644_CR18","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1111\/jsm.12130","volume":"10","author":"J Buvat","year":"2013","unstructured":"Buvat J, Buttner H, Hatzimouratidis K, Vendeira PA, Moncada I et al (2013) Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction. J Sex Med 10:1592\u20131602","journal-title":"J Sex Med"},{"key":"1644_CR19","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1743-6109.2008.00774.x","volume":"5","author":"HM Conaglen","year":"2008","unstructured":"Conaglen HM, Conaglen JV (2008) Investigating women\u2019s preference for sildenafil or tadalafil use by their partners with erectile dysfunction: the partners\u2019 preference study. J Sex Med 5:1198\u20131207","journal-title":"J Sex Med"},{"key":"1644_CR20","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/j.1464-410X.2005.05892.x","volume":"96","author":"I Eardley","year":"2005","unstructured":"Eardley I, Mirone V, Montorsi F, Ralph D, Kell P et al (2005) An open-label, multicentre, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in men naive to phosphodiesterase 5 inhibitor therapy. BJU Int 96:1323\u20131332","journal-title":"BJU Int"},{"key":"1644_CR21","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1016\/S0149-2918(03)80328-4","volume":"25","author":"F Govier","year":"2003","unstructured":"Govier F, Potempa AJ, Kaufman J, Denne J, Kovalenko P et al (2003) A multicenter, randomized, double-blind, crossover study of patient preference for tadalafil 20\u00a0mg or sildenafil citrate 50\u00a0mg during initiation of treatment for erectile dysfunction. Clin Ther 25:2709\u20132723","journal-title":"Clin Ther"},{"key":"1644_CR22","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/ijir.2014.15","volume":"26","author":"K Hatzimouratidis","year":"2014","unstructured":"Hatzimouratidis K, Buvat J, Buttner H, Vendeira PA, Moncada I et al (2014) Psychosocial outcomes after initial treatment of erectile dysfunction with tadalafil once daily, tadalafil on demand or sildenafil citrate on demand: results from a randomized, open-label study. Int J Impot Res 26:223\u2013229","journal-title":"Int J Impot Res"},{"key":"1644_CR23","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1111\/j.1743-6109.2012.02667.x","volume":"9","author":"E Rubio-Aurioles","year":"2012","unstructured":"Rubio-Aurioles E, Porst H, Kim ED, Montorsi F, Hackett G et al (2012) A randomized open-label trial with a crossover comparison of sexual self-confidence and other treatment outcomes following tadalafil once a day vs. tadalafil or sildenafil on-demand in men with erectile dysfunction. J Sex Med 9:1418\u20131429","journal-title":"J Sex Med"},{"key":"1644_CR24","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1743-6109.2006.00297.x","volume":"3","author":"JR Tolra","year":"2006","unstructured":"Tolra JR, Campana JM, Ciutat LF, Miranda EF (2006) Prospective, randomized, open-label, fixed-dose, crossover study to establish preference of patients with erectile dysfunction after taking the three PDE-5 inhibitors. J Sex Med 3:901\u2013909","journal-title":"J Sex Med"},{"issue":"499\u2013507","key":"1644_CR25","first-page":"507","volume":"45","author":"A Keitz von","year":"2004","unstructured":"von Keitz A, Rajfer J, Segal S, Murphy A, Denne J et al (2004) A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil. Eur Urol 45(499\u2013507):507\u2013509","journal-title":"Eur Urol"},{"key":"1644_CR26","doi-asserted-by":"crossref","first-page":"773","DOI":"10.4103\/1008-682X.159719","volume":"18","author":"HJ Li","year":"2016","unstructured":"Li HJ, Bai WJ, Dai YT, Xu WP, Wang CN et al (2016) An analysis of treatment preferences and sexual quality of life outcomes in female partners of Chinese men with erectile dysfunction. Asian J Androl 18:773\u2013779","journal-title":"Asian J Androl"},{"key":"1644_CR27","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1590\/S1677-5538.IBJU.2014.03.14","volume":"40","author":"C Cairoli","year":"2014","unstructured":"Cairoli C, Reyes LA, Henneges C, Sorsaburu S (2014) PDE5 inhibitor treatment persistence and adherence in Brazilian men: post hoc analyses from a 6-month, prospective, observational study. Int Braz J Urol 40:390\u2013399","journal-title":"Int Braz J Urol"},{"key":"1644_CR28","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1016\/S0149-2918(03)80329-6","volume":"25","author":"P Stroberg","year":"2003","unstructured":"Stroberg P, Murphy A, Costigan T (2003) Switching patients with erectile dysfunction from sildenafil citrate to tadalafil: results of a European multicenter, open-label study of patient preference. Clin Ther 25:2724\u20132737","journal-title":"Clin Ther"},{"key":"1644_CR29","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1745-7262.2007.00319.x","volume":"9","author":"TY Ahn","year":"2007","unstructured":"Ahn TY, Lee SW, Kim SW, Yang DY, Park NC et al (2007) Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil. Asian J Androl 9:760\u2013770","journal-title":"Asian J Androl"},{"key":"1644_CR30","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1185\/03007995.2013.791263","volume":"29","author":"A El-Meliegy","year":"2013","unstructured":"El-Meliegy A, Rabah D, Al-Mitwalli K, Mostafa T, Hussein T et al (2013) A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction. Curr Med Res Opin 29:707\u2013717","journal-title":"Curr Med Res Opin"},{"key":"1644_CR31","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/j.1464-410X.2008.08328.x","volume":"103","author":"J Taylor","year":"2009","unstructured":"Taylor J, Baldo OB, Storey A, Cartledge J, Eardley I (2009) Differences in side-effect duration and related bother levels between phosphodiesterase type 5 inhibitors. BJU Int 103:1392\u20131395","journal-title":"BJU Int"},{"key":"1644_CR32","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1179\/2045772312Y.0000000004","volume":"35","author":"N Rizio","year":"2012","unstructured":"Rizio N, Tran C, Sorenson M (2012) Efficacy and satisfaction rates of oral PDE5is in the treatment of erectile dysfunction secondary to spinal cord injury: a review of literature. J Spinal Cord Med 35:219\u2013228","journal-title":"J Spinal Cord Med"},{"key":"1644_CR33","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1471-2490-14-52","volume":"14","author":"Z Tang","year":"2014","unstructured":"Tang Z, Li D, Zhang X, Yi L, Zhu X et al (2014) Comparison of the simplified International Index of Erectile Function (IIEF-5) in patients of erectile dysfunction with different pathophysiologies. BMC Urol 14:52","journal-title":"BMC Urol"},{"key":"1644_CR34","first-page":"820","volume":"94","author":"KT Rew","year":"2016","unstructured":"Rew KT, Heidelbaugh JJ (2016) Erectile dysfunction. Am Fam Physician 94:820\u2013827","journal-title":"Am Fam Physician"},{"key":"1644_CR35","first-page":"1146","volume":"17","author":"W Wang","year":"2011","unstructured":"Wang W (2011) Psychological factors involved in erectile dysfunction. Zhonghua Nan Ke Xue 17:1146\u20131151","journal-title":"Zhonghua Nan Ke Xue"},{"key":"1644_CR36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/ijir.2013.31","volume":"26","author":"A Sontag","year":"2014","unstructured":"Sontag A, Ni X, Althof SE, Rosen RC (2014) Relationship between erectile function and sexual self-confidence: a path analytic model in men being treated with tadalafil. Int J Impot Res 26:7\u201312","journal-title":"Int J Impot Res"},{"key":"1644_CR37","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1159\/000444860","volume":"98","author":"G Li","year":"2017","unstructured":"Li G, Lan H, Liang J, Zhang C, Huang C (2017) Efficacy of tadalafil de-escalation in the treatment of psychogenic erectile dysfunction. Urol Int 98:205\u2013209","journal-title":"Urol Int"},{"key":"1644_CR38","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0022-5347(05)61093-2","volume":"173","author":"PC Albertsen","year":"2005","unstructured":"Albertsen PC (2005) Development and validation of the self-esteem and relationship (SEAR) Questionnaire in erectile dysfunction. J Urol 173:1328","journal-title":"J Urol"},{"key":"1644_CR39","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S0090-4295(98)00582-2","volume":"53","author":"SE Althof","year":"1999","unstructured":"Althof SE, Corty EW, Levine SB, Levine F, Burnett AL et al (1999) EDITS: development of questionnaires for evaluating satisfaction with treatments for erectile dysfunction. Urology 53:793\u2013799","journal-title":"Urology"},{"key":"1644_CR40","first-page":"407","volume":"38","author":"SA Huang","year":"2013","unstructured":"Huang SA, Lie JD (2013) Phosphodiesterase-5 (PDE5) inhibitors in the management of erectile dysfunction. P T 38:407\u2013419","journal-title":"P T"},{"key":"1644_CR41","doi-asserted-by":"crossref","first-page":"61","DOI":"10.4103\/1008-682X.143244","volume":"17","author":"WJ Bai","year":"2015","unstructured":"Bai WJ, Li HJ, Dai YT, He XY, Huang YR et al (2015) An open-label, multicenter, randomized, crossover study comparing sildenafil citrate and tadalafil for treating erectile dysfunction in Chinese men naive to phosphodiesterase 5 inhibitor therapy. Asian J Androl 17:61\u201367","journal-title":"Asian J Androl"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11255-017-1644-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-017-1644-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-017-1644-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T15:05:08Z","timestamp":1719327908000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11255-017-1644-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["1644"],"URL":"https:\/\/doi.org\/10.1007\/s11255-017-1644-5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727842810.793555219","asserted-by":"object"}]},"ISSN":["0301-1623","1573-2584"],"issn-type":[{"value":"0301-1623","type":"print"},{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,24]]}}}